Mercator Medical stock rebounds as first-half profit reaches PLN 57.7 million

Mercator Medical's first-half recovery has put profitability back at the centre of the investment case. In its October 1, 2026 report, the company said consolidated revenue reached PLN 337.2 million in the first half of 2026, up 16% year over year. Net profit rose 170% to PLN 57.7 million, while EBITDA increased to PLN 61.4 million from a loss of PLN 0.7 million a year earlier.

Margins drive the recovery

The company attributed the improvement primarily to wider margins, a more favourable sales mix and better purchasing terms for some goods. Higher selling prices and volumes in diagnostic gloves supported revenue, while optimisation, automation and broader sourcing helped contain manufacturing costs.

Management nevertheless expects demand to stabilise in the coming quarters and warned that elevated production and purchasing costs could affect margins. Raw-material, energy, logistics and transport-market volatility remain relevant risks for the glove business.

International sales remain important

The United States accounted for 40.6% of first-half sales, with revenue there reaching almost PLN 136.8 million and rising 29.3% year over year. Sales in Poland increased 17.1% to PLN 81 million, while the Czech Republic and Germany also posted growth. Romania was the exception among the leading markets, with sales down 11%.

Mercator Medical also reported stronger contributions from complementary products. Nonwovens revenue rose 26.1% to PLN 21.2 million, and household-glove volumes increased to 21.4 million pieces from 5.1 million in the comparable period. The cogeneration project at the Thailand plant was described as being in its final implementation stage and could support manufacturing efficiency.

Late quote and investor context

Lang & Schwarz showed Mercator Medical at 13.42 euros on October 29, 2026, at 22:59:56 Berlin time. A compatible dated Xetra closing comparison is not included here, so no daily percentage change is stated. Investors can access the real-time quote of Mercator Medical stock separately.

In the broader Polish market, investors can follow the WIG20 for a large-cap reference.

For more news and analyses on Mercator Medical stock, see the dedicated topic page.